Reference products and why people stop using them — internal hemorrhoids office based treatment

1. Summary

Office-based treatment of grade I–III internal hemorrhoids rests on three established modalities — rubber band ligation (RBL), infrared coagulation (IRC), and sclerotherapy — which a 2025 JAMA review and the AGA's 2026 Clinical Practice Update both describe as safe, effective, first-line options ahead of surgical hemorrhoidectomy [1][2]. The clearest documented reason people leave RBL specifically at grade III is recurrence: the one randomized trial that isolated grade III disease found RBL recurrence more than seven times higher than hemorrhoidectomy at 12 months [3][4]. Two independent studies of Doppler-guided hemorrhoidal artery ligation (HAL), a step between office therapy and excision, agree that Doppler guidance itself does not reduce recurrence risk over non-Doppler HAL [5][6]. On the device side, the FDA's 510(k) record shows a 510(k)-exempt banding-instrument class, a four-clearance RF/electrocautery lineage that has changed hands from a small firm to a large strategic, and one full-grade-range coagulation device whose entire commercial product line was recalled in 2016–2017 for a quality-system deficiency unrelated to any stated efficacy finding [9]–[16].

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Office-based first-line modalities: rubber band ligation, infrared coagulation, sclerotherapy

A 2025 JAMA narrative review and the AGA's 2026 Clinical Practice Update independently agree that hemorrhoid banding and infrared coagulation are appropriate office-based first-line procedural treatments for grade I–III internal hemorrhoids, to be used before surgical hemorrhoidectomy, with escalation to surgery for grade III disease that fails banding or for grade IV disease [1][2]. Beyond that consensus, the specific efficacy and retreatment figures below come from the JAMA review alone and are not independently corroborated by another primary source located this pass — carried here as [single-source]:

• RBL "resolves symptoms in 89% of patients," but "repeated banding is needed in up to 20%" [single-source, 1].
• IRC yields "70% to 80% success in reducing bleeding and prolapse" [single-source, 1].
• Sclerotherapy is "efficacious in the short term (weeks to months) among 70% to 85% of patients, but long-term remission occurs in only one-third of patients" [single-source, 1].

The one study located this pass that isolated grade III disease specifically, rather than pooling grades I–III, found a materially different picture for RBL. In a 10-Dutch-hospital, open-label, randomized noninferiority trial (n=87: 47 RBL, 40 hemorrhoidectomy; NCT04621695), "recurrence rate was worse in the rubber band ligation group (47.5% vs 6.1%), with an absolute risk difference of 41% (95% CI, 24%-59%)," and RBL "was not noninferior to hemorrhoidectomy" on 12-month quality-adjusted life years — while the RBL arm returned to work sooner (median 1 vs 9 days) and reported lower first-week pain [single-source, 3][4]. The trial's own stated limitation is early termination for funding, "resulting in a relatively small sample size and limited statistical power" [3]. No second grade-III-isolated RCT was located to corroborate or contest this finding.

Escalation short of excision: Doppler-guided hemorrhoidal artery ligation (HAL)

HAL — with mucopexy, with or without Doppler probe guidance — sits between office therapy and excisional surgery. Two independent, non-affiliated sources agree that Doppler guidance itself does not reduce recurrence: a systematic review and meta-analysis of five comparative studies found "non-DG patients were less likely to experience recurrence" than DG patients (OR 5.12, P<0.001), concluding "non-inferiority of the non-DG HAL-RAR procedure" [5]; a separate single-center cohort (n=122 grade II–III patients, Chivasso Hospital, Italy, median follow-up 46 months) found recurrence of 23.7% (DG-HAL) versus 28.3% (HAL, no Doppler), not a statistically significant difference (P=0.574), and concluded "the use of DG did not reduce recurrence risk" while "operative time was significantly increased in the DG-HAL group" [6]. Read together, these undercut the rationale for the added cost and time of Doppler probes specifically, without undercutting HAL as a modality.

The surgical comparator: stapled hemorrhoidopexy

Two single-source, non-overlapping cohorts describe stapled hemorrhoidopexy's own long-run attrition. A very-long-follow-up study (n=98 of an original 155 patients, mean follow-up 193 months) found recurrence "higher in grade IV (26.1%) than in grade III (7.7%)," with 11.2% of patients requiring reoperation and 82.5% "very satisfied or satisfied" [single-source, 7]. A separate cohort using newer "high-volume" stapling devices (n=59, grade II–IV, median follow-up 70.5 months) reported a recurrence rate of 5.1%, with the authors attributing the improvement over older low-volume staplers to the device generation itself [single-source, 8]. Neither study is US-based or randomized; no head-to-head trial against RBL or HAL isolating grade III alone was located this pass.

Cleared devices, and what happened to them after clearance

FDA's device-name search returns only two 510(k)s with "hemorrhoid" in the device name: the Nexus Hemorrhoid Ligator (K131282, Inx Medical, decided 2013-07-11) and the EEA Hemorrhoid Stapler and Accessories (K083781, Covidien, decided 2009-02-04), cleared "for surgical treatment of hemorrhoidal disease" throughout the anal canal [9][11]. Banding hardware itself sits in a 510(k)-exempt product class — "Ligator, Hemorrhoidal," product code FHN, 21 CFR 876.4400 — so a follower banding device faces no premarket-notification barrier [10].

The RF/electrocautery predicate class tells a different story: the HET Bipolar Electrocautery Forceps/Monitor family, product code GEI (21 CFR 878.4400), carries a four-clearance history — K110143 (2011-06-02), K121085 (2012-11-20), K140422 (2014-06-05), all Het Systems, LLC, and K200146 (2020-05-07), Covidien, LLC — showing the device line moved from a small firm to a large strategic acquirer over nine years [12][13]. The Ultroid Hemorrhoid Management System, product code KNS (21 CFR 876.4300), was cleared in 2003 (K030315) for "coagulative hemostatic therapy of internal hemorrhoids grades I, II, III, IV" — the only located device whose indication spans the full grade range [14][15]. In 2016–2017, Ultroid Technologies, Inc. recalled its entire commercial line — the console/generator, the mobile battery unit, the procedure pack, and the disposable probes sold individually — with FDA recording the reason as failure to be "designed, qualified, manufactured, and/or managed under a state of control per internal quality system procedures," i.e., a Quality System Regulation deficiency, not a stated efficacy or safety finding about the therapy itself [16]. No recall was located for the FHN (banding) or GEI (HET) product families in this device area.

4. Sources

[1] Hemorrhoidal Disease: A Review — JAMA (published 2025-08-18; accessed 2026-09-01). PMID 40824576 — https://pubmed.ncbi.nlm.nih.gov/40824576/ [peer-reviewed] [2] AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review — Clinical Gastroenterology and Hepatology (published 2026-07, day not given in the PubMed record; accessed 2026-09-01). PMID 42067175 — https://pubmed.ncbi.nlm.nih.gov/42067175/ [guideline] [3] Comparison of Rubber Band Ligation and Hemorrhoidectomy in Patients With Symptomatic Hemorrhoids Grade III: A Multicenter, Open-Label, Randomized Controlled Noninferiority Trial — Diseases of the Colon & Rectum (published 2025-05-01; accessed 2026-09-01). PMID 39952268 — https://pubmed.ncbi.nlm.nih.gov/39952268/ [peer-reviewed] [4] Comparison of Rubber Band Ligation and Haemorrhoidectomy in Patients With Symptomatic Haemorrhoids Grade III — ClinicalTrials.gov (registered 2021-03-16; accessed 2026-09-01). NCT04621695 — https://clinicaltrials.gov/study/NCT04621695 [trial-registry] [5] Haemorrhoid artery ligation - recto anal repair (HAL-RAR) blind versus Doppler: a systematic review and meta-analysis — ANZ Journal of Surgery (published 2024-11, day not given in the PubMed record; accessed 2026-09-01). PMID 39465535 — https://pubmed.ncbi.nlm.nih.gov/39465535/ [peer-reviewed] [6] Hemorrhoidal Artery Ligation for the Treatment of Grade II-III Hemorrhoids: Is it Worth the Use of Doppler Guide in Long-Term Follow-Up? A Single-Center Cohort Study — Annals of Surgery Open (published 2023, month not given in the PubMed record; accessed 2026-09-01). PMID 37601476 — https://pubmed.ncbi.nlm.nih.gov/37601476/ [peer-reviewed] [7] Stapled Hemorrhoidopexy: Results, Late Complications, and Degree of Satisfaction After 16 Years of Follow-up — Arquivos Brasileiros de Cirurgia Digestiva (published 2022, month not given in the PubMed record; accessed 2026-09-01). PMID 36134815 — https://pubmed.ncbi.nlm.nih.gov/36134815/ [peer-reviewed] [8] Long-Term Outcomes of High-Volume Stapled Hemorrhoidopexy to Treat Symptomatic Hemorrhoidal Disease — Annals of Coloproctology (published 2023-02, day not given in the PubMed record; accessed 2026-09-01). PMID 34324801 — https://pubmed.ncbi.nlm.nih.gov/34324801/ [peer-reviewed] [9] 510(k) Summary K083781 — EEA Hemorrhoid Stapler and Accessories, Covidien — FDA (decided 2009-02-04; accessed 2026-09-01). K083781 — https://www.accessdata.fda.gov/cdrh_docs/pdf8/K083781.pdf [federal-registry] [10] Device Classification, product code FHN, "Ligator, Hemorrhoidal" — FDA/openFDA (regulation on file, no date given in the record; accessed 2026-09-01). 21 CFR 876.4400 — https://api.fda.gov/device/classification.json?search=product_code:FHN [federal-registry] [11] 510(k) Summary K131282 — Nexus Hemorrhoid Ligator, Inx Medical — FDA (decided 2013-07-11; accessed 2026-09-01). K131282 — https://www.accessdata.fda.gov/cdrh_docs/pdf13/K131282.pdf [federal-registry] [12] 510(k) clearances for the "HET Bipolar" device family, Het Systems, LLC / Covidien, LLC — FDA (decided 2011-06-02 through 2020-05-07; accessed 2026-09-01). K110143, K121085, K140422, K200146 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200146 [federal-registry] [13] Device Classification, product code GEI, "Electrosurgical, Cutting & Coagulation & Accessories" — FDA/openFDA (regulation on file, no date given in the record; accessed 2026-09-01). 21 CFR 878.4400 — https://api.fda.gov/device/classification.json?search=product_code:GEI [federal-registry] [14] 510(k) Summary K030315 — Ultroid Hemorrhoid Management System, Ultroid, LLC — FDA (decided 2003-02-27; accessed 2026-09-01). K030315 — https://www.accessdata.fda.gov/cdrh_docs/pdf3/K030315.pdf [federal-registry] [15] Device Classification, product code KNS, "Unit, Electrosurgical, Endoscopic" — FDA/openFDA (regulation on file, no date given in the record; accessed 2026-09-01). 21 CFR 876.4300 — https://api.fda.gov/device/classification.json?search=product_code:KNS [federal-registry] [16] Recall Z-0782-2017 (and related Z-0783/0784/0785-2017) — Ultroid Technologies, Inc., Ultroid Hemorrhoid Management Systems and Procedures Kit — FDA (event initiated 2016-10-19, status Terminated; accessed 2026-09-01). Z-0782-2017 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry]

5. Sourcing & Gaps

Well established: The treatment-ladder consensus — RBL and IRC as first-line office procedures for grade I–III disease, ahead of surgical hemorrhoidectomy, with grade IV or banding-refractory grade III referred to surgery — rests on two independent, non-affiliated society-level sources, JAMA [1] and AGA [2]. The finding that Doppler guidance does not reduce HAL recurrence rests on two independent, non-affiliated primary sources, a five-study meta-analysis [5] and a separate single-center cohort [6].

Thin: The specific RBL/IRC/sclerotherapy efficacy and retreatment percentages (89% symptom resolution, up to 20% repeat banding, 70–80% IRC success, 70–85% sclerotherapy short-term efficacy with one-third long-term remission) rest on the JAMA review alone [single-source, 1], which is itself a narrative review without a stated primary source for these figures. The grade-III-isolated RBL-vs-hemorrhoidectomy recurrence gap (47.5% vs 6.1%) rests on one early-terminated, underpowered RCT [single-source, 3][4]. Both stapled-hemorrhoidopexy long-term recurrence figures (7.7%/26.1% by grade; 5.1% with newer devices) each rest on one non-US, non-randomized cohort [single-source, 7][8].

Rescoped from class 3: The underlying desirability question for this section — "would clinicians or patients abandon rubber band ligation, infrared coagulation, or sclerotherapy in favor of a new office-based device?" — is a class-3 stakeholder-future question and is not answered here. This report instead answers its revealed-behaviour twin: what recurrence, retreatment, and complication rates the published literature reports for each incumbent modality, and what regulatory actions (clearance history, recalls) followed the devices that deliver them (docs/research-lane-spec.md §3.1).

Out of scope: CPT/HCPCS descriptor text and any professional-fee pricing (AMA-licensed; scoped to this domain's reimbursement section, not this one). MAUDE adverse-event narratives — no connector in this repo queries MAUDE. Non-US clearance or reimbursement records — no connector in this repo queries a non-US device registry.

Not searched vs. not found: A branded CRH-style ("O'Regan") disposable banding system was searched for by name in PubMed ("CRH O'Regan hemorrhoid banding system disposable") and returned no records in a 15-year window — not found by that query, not confirmed absent from the literature under other phrasing, which was not tried. A 510(k) lookup combining device_name "hemorrhoid" with applicant "CRH Medical" returned no match — not found under that combination; a broader applicant-only or brand-name 510(k) sweep for CRH-branded hardware was not run. A 510(k) lookup for "transanal hemorrhoidal dearterialization" (the generic name for THD-branded Doppler ligation devices) returned no match — not found under that exact device-name string; THD under its own brand name or applicant name was not separately searched. Grade-III-isolated, US-population recurrence or retreatment cohorts for RBL, IRC, or sclerotherapy were not located for any of the three office modalities; whether any exists was not exhaustively searched beyond the queries run this pass.

[inference] The recall reason recorded for the Ultroid line — a Quality System Regulation deficiency — says nothing about whether the coagulative-hemostasis therapy itself works; reading it as an efficacy signal would be an inference this report does not draw. Separately, the recurring pattern across the office-based and surgical literature located this pass — that grade III recurrence is consistently reported higher than grade I–II or is the specific subgroup where a less invasive modality (RBL) underperforms a more invasive one (hemorrhoidectomy) — is this writer's own reading across sources [3][4][7], not a stated finding of any single one of them.

6. Claim Candidates